Radnor Capital Management LLC Makes New Investment in Quest Diagnostics Incorporated (NYSE:DGX)

Radnor Capital Management LLC acquired a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,602 shares of the medical research company’s stock, valued at approximately $249,000.

Several other institutional investors also recently made changes to their positions in DGX. Legacy Financial Advisors Inc. grew its position in Quest Diagnostics by 1.6% during the second quarter. Legacy Financial Advisors Inc. now owns 4,697 shares of the medical research company’s stock valued at $643,000 after acquiring an additional 72 shares during the period. Meeder Advisory Services Inc. grew its holdings in shares of Quest Diagnostics by 4.9% during the 2nd quarter. Meeder Advisory Services Inc. now owns 1,795 shares of the medical research company’s stock worth $246,000 after purchasing an additional 84 shares during the period. Keudell Morrison Wealth Management raised its holdings in Quest Diagnostics by 3.8% in the first quarter. Keudell Morrison Wealth Management now owns 2,312 shares of the medical research company’s stock valued at $308,000 after buying an additional 85 shares during the period. Arjuna Capital lifted its position in Quest Diagnostics by 5.2% during the first quarter. Arjuna Capital now owns 1,770 shares of the medical research company’s stock valued at $236,000 after buying an additional 88 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in Quest Diagnostics by 6.8% during the third quarter. Blue Trust Inc. now owns 1,392 shares of the medical research company’s stock worth $216,000 after buying an additional 89 shares during the period. 88.06% of the stock is owned by hedge funds and other institutional investors.

Quest Diagnostics Stock Up 0.7 %

DGX stock opened at $156.20 on Friday. Quest Diagnostics Incorporated has a twelve month low of $123.04 and a twelve month high of $160.95. The company has a current ratio of 1.25, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $17.43 billion, a P/E ratio of 20.99, a PEG ratio of 2.67 and a beta of 0.89. The firm has a 50 day simple moving average of $153.48 and a 200-day simple moving average of $146.40.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.26 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.25%. The business had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.43 billion. During the same quarter last year, the company earned $2.22 earnings per share. The business’s quarterly revenue was up 8.5% compared to the same quarter last year. On average, equities research analysts predict that Quest Diagnostics Incorporated will post 8.9 earnings per share for the current fiscal year.

Quest Diagnostics Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, October 21st. Shareholders of record on Friday, October 4th were issued a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.92%. The ex-dividend date of this dividend was Friday, October 4th. Quest Diagnostics’s dividend payout ratio is presently 40.32%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DGX shares. Baird R W raised shares of Quest Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 23rd. Evercore ISI began coverage on Quest Diagnostics in a research report on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price objective on the stock. Piper Sandler upped their target price on Quest Diagnostics from $150.00 to $165.00 and gave the stock a “neutral” rating in a research report on Monday, October 28th. Robert W. Baird upgraded Quest Diagnostics from a “neutral” rating to an “outperform” rating and increased their target price for the company from $157.00 to $182.00 in a research note on Wednesday, October 23rd. Finally, Truist Financial boosted their price target on Quest Diagnostics from $158.00 to $165.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Nine equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $164.58.

Insiders Place Their Bets

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,775 shares of Quest Diagnostics stock in a transaction on Monday, October 28th. The shares were sold at an average price of $156.92, for a total value of $278,533.00. Following the completion of the transaction, the senior vice president now owns 9,734 shares of the company’s stock, valued at $1,527,459.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Quest Diagnostics news, CAO Michael J. Deppe sold 18,755 shares of Quest Diagnostics stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $154.05, for a total value of $2,889,207.75. Following the completion of the transaction, the chief accounting officer now owns 34,941 shares of the company’s stock, valued at $5,382,661.05. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Karthik Kuppusamy sold 1,775 shares of Quest Diagnostics stock in a transaction on Monday, October 28th. The stock was sold at an average price of $156.92, for a total transaction of $278,533.00. Following the completion of the transaction, the senior vice president now directly owns 9,734 shares of the company’s stock, valued at approximately $1,527,459.28. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,520 shares of company stock valued at $3,472,728 over the last 90 days. 0.79% of the stock is owned by company insiders.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.